Articles tagged with Blood Diseases
A phase 3 clinical trial found romiplostim significantly reduced chemotherapy dose delays and improved platelet counts in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The therapy enables patients to maintain chemotherapy intensity, potentially preserving the integrity of cancer c...
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
Researchers developed a biomimetic platform to enhance CAR T cell therapy against leukemia by creating a molecular bridge that reinforces the interface between CAR T cells and leukemia cells. This platform, called FACE, uses ferritin to bind to CD71 on leukemia cells, improving cell recognition and elimination.
Researchers at the Center for Cell-Based Therapy developed a new approach to enhance CAR-NK cell cytotoxicity, combining optimized co-stimulation with reversible pharmacological control. The study showed increased tumor control in animal models, paving the way for improved cancer treatment.
A large registry study identifies a specific genetic mismatch linked to severe acute graft-versus-host disease (aGVHD) after cord blood transplantation, tripling the risk of life-threatening complications. Researchers found that a particular HLA combination in donors and recipients increased aGVHD risk by threefold.
A group of nerve cells in the brainstem has been identified as a stabilizing system for blood pressure, preventing fluctuations between daily activities. The study suggests that loss or dysfunction of these cells can lead to unstable blood pressure and is associated with conditions such as multiple system atrophy.
Dr. Zon's pioneering research has illuminated how blood develops in embryos, leading to a deeper understanding of rare blood diseases, including pregnancy complications. His discoveries have also led to breakthrough treatments for genetic blood disorders affecting babies and children.
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.
Researchers identify sequence-dependent RNA splicing abnormalities in 36% of pediatric AML cases, linked to lower complete remission rates and poorer survival. Functional dysregulation of U2AF2 protein drives aberrant splicing, which can be targeted by pharmacological modulation of PRMT enzymes.
A global study evaluates whether a new early-warning platform can support earlier interventions against dengue outbreaks. The E-Dengue platform, tailored for district-level decision-making, has been integrated into Vietnam's routine dengue surveillance and will be tested in a large cluster randomized controlled trial.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
A team of researchers has identified two proteins critical to the destruction of red blood cells by the Oroya fever pathogen. This discovery paves the way for a potential novel therapy against this deadly neglected tropical disease.
A large-scale study identified risk factors and clinical features of ICI-ITP, a rare but serious complication of anti-cancer immunotherapy. The study found that patients with ICI-ITP tend to have lower platelet counts at the start of treatment, experience additional immune-related adverse events, and have a higher risk of death.
A Phase III clinical trial found that over half of patients who received ianalumab for primary ITP maintained safe platelet counts without serious bleeding episodes for at least one year. The study suggests a new treatment option with the potential to improve long-term quality of life for patients.
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
A new study presented at the 2025 American Society of Hematology meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma. The research found that damaged 3D genome architecture can silence key tumor suppressor genes, creating fertile ground for malignancy.
Fred Hutch experts will present CAR-T access expansion, new AML treatment strategies, and the impact of climate on cancer. Experts discuss optimizing maintenance therapy using MRD-directed approaches for high-risk AML patients and evaluating the safety & efficacy of combining PIVEK with FLAG-IDA for adults with untreated AML.
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
A new study from Cincinnati Children's reveals how Fanconi anemia disrupts energy pathways and affects glucose metabolism, paving the way for targeted dietary interventions to improve health and reduce cancer risk. The research uses isotope tracing metabolomics to track nutrient metabolism in people with FA.
A new study found that engasertib reduced nosebleed frequency and duration in patients with hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder. The trial also showed improved symptoms and safety profile for the drug, paving the way for its potential use as a treatment option.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
Scientists have created a complex tissue model of human bone marrow using only human cells, replicating the cellular complexity of the body's 'blood factory'. This breakthrough reduces the need for animal experiments in blood cancer research and potentially enables personalized therapies.
Researchers at Kyoto University create a method to produce platelet-producing cells from stem cells, offering an unlimited supply of patient-derived platelets. Monitoring KAT7 levels can help ensure efficient and consistent platelet manufacturing.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
A study of 169 patients with porto-sinusoidal vascular disease found that portal vein thrombosis was associated with higher rates of esophageal variceal bleeding, ascites, and antithrombin III deficiency. The study also reported a higher risk of mortality in patients with PVT compared to those without.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
A recent study published in Leukemia found that age-based classifications in acute myeloid leukemia (AML) treatment may be outdated. The research analyzed data from 2,823 adult AML patients, revealing nuanced age-related trends in genetic mutations and survival outcomes.
Researchers at the University of Cambridge have developed a new lab-grown human embryo model that replicates early human development, including the production of blood stem cells. The 'hematoids' model mimics the natural developmental process, offering potential medical advances in screening drugs and studying blood disorders.
A team of researchers led by Dr. Manel Esteller has published a study on the longest-lived person ever recorded, Maria Branyas, who reached 117 years. The analysis reveals a fascinating duality: simultaneous presence of signals of extreme aging and healthy longevity. Despite signs of aging, Branyas had genetic characteristics associate...
A new study assesses ChatGPT 3.5's performance on hematology-oncology tasks, revealing its strengths and limitations in providing accurate information for patients. The study highlights the importance of physician oversight when using AI-generated medical information.
A subanalysis of the LoDoCo2 trial found that low-dose colchicine slows the growth of clonal hematopoiesis, a common acquired gene mutation linked to cardiovascular disease and cancer. Colchicine was associated with significantly attenuated clonal growth in TET2-mutated CH.
Researchers have developed a new epigenetic editing method using CRISPR technology, which can switch genes back on by removing methyl groups attached to silenced or suppressed genes. This approach shows promise for treating people with Sickle Cell-related diseases, reducing the risk of unwanted changes and potential health problems.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
The DKMS John Hansen Research Grant is supporting innovative research projects in blood cancer therapy, aiming to improve treatment outcomes. The grant, worth almost €1 million, will support young scientists with a focus on transplant immunology and novel diagnostic and therapeutic strategies.
Researchers at University of Pennsylvania discover red blood cells contribute to clot contraction, shrinking and stabilizing blood clots. The finding opens door to new strategies for studying and treating clotting disorders, such as excessive bleeding or dangerous clots like those seen in strokes.
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
A recent study found that blood cancer patients achieve good outcomes with a partial match drawn from the national public registry of donors when treated with cyclophosphamide. Survival rates at one year were comparable to those seen in other studies with fully matched donors.
Researchers identified a gene mutation that disrupts iron absorption in patients with Crohn's disease, leading to persistent anemia. The study sheds light on how genetic risk factors for IBD can compound patient symptoms by interfering with nutrient absorption.
The study identified key proteins and signaling pathways involved in CAR-T cell therapy's efficacy, including cytokines, kinases, receptors, proteases, and chemical messengers. The findings pave the way for new treatment advances and potential biomarkers.
A new study published in Blood Cancer Discovery found that certain gene mutations and the maturity of leukemia cells affect how patients respond to venetoclax and hypomethylating agents. Researchers identified a subtype of acute myeloid leukemia with worse outcomes, particularly those without the NPM1 mutation.
A new partnership between Murdoch Children's Research Institute and Retro Biosciences will advance personalized therapies for children and adults with bone marrow failure, leukaemia, and other blood disorders. The $35M agreement aims to develop autologous therapies using the breakthrough blood stem cell discovery.
A new partnership between Murdoch Children's Research Institute and Retro Biosciences aims to develop personalized blood stem cell treatments for children and adults with blood disorders. The collaboration has the potential to prevent complications from mismatched donors by using a patient's own perfectly matched cells in transplants.
A recent study found that strict adherence to High-Throughput Sequencing (HTS) technology based carrier screening can achieve high efficiency in preventing severe thalassemia birth defects. The study identified 15.07% of women as carriers of thalassemia and confirmed 59 fetuses with severe thalassemia, all of which were in high-risk co...
A new CAR-T therapy, HSP-CAR30, has achieved positive results in a high proportion of patients with refractory CD30+ lymphoma. The treatment promotes the expansion of memory T cells, leading to durable responses and improved clinical outcomes.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
A new imaging technique developed by IU scientists allows for the visualization of 25 cellular markers in intact bone marrow tissue without disruption. This advancement could support future drug development and therapies for conditions involving bone marrow.
A new study found that limiting TV viewing to one hour or less daily may help offset an increased risk of heart and blood vessel diseases for people with a genetic risk for Type 2 diabetes. This suggests that reducing TV watching could serve as a key behavioral target for preventing atherosclerotic cardiovascular diseases linked to Typ...
A new study by researchers at UCSF has found that long-acting injectable treatments can be transformative for patients who struggle to take daily HIV pills, resulting in undetectable viral loads and improved health outcomes. The treatment approach could help stop the spread of HIV by keeping more patients from being infectious.
Dr. Gordon Keller's groundbreaking research on directed differentiation of human pluripotent stem cells has illuminated the path to transforming human health. His lab's world-first discovery and pioneering efforts have pushed the boundaries of what is possible, offering hope for regenerating heart, liver, and blood cells.
A Texas A&M University researcher found that reducing alcohol consumption aligns with a harm reduction approach, which may be a more feasible approach for high-risk college drinkers. The study surveyed 822 high-risk college students and analyzed their intention to reduce drinking using the Theory of Planned Behavior.
Researchers found a common cause and potential treatment for 'smooth brain' disorders like lissencephaly, identifying dysregulation in the mTOR pathway. The study suggests a single treatment approach could benefit patients across the lissencephaly spectrum.
A study led by Henry J. Pownall and Khurram Nasir found a strong link between the amount of free cholesterol in HDL and its accumulation in macrophages, which can contribute to heart disease. The researchers aim to develop new diagnostics and treatments for managing heart disease using HDL-free cholesterol as a biomarker.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
The myeloMATCH program aims to improve precision medicine by matching patients with specific genetic signatures of their disease. Patients receive tailored treatment options based on the unique makeup of their cancer, offering hope for improved outcomes and increased survival rates.
A new treatment shows promise for people with high-risk smoldering multiple myeloma, delaying cancer progression and improving overall survival. Daratumumab significantly reduces risk of progression to active disease and improves patient outcomes.
Researchers are working to develop a curative treatment for multiple myeloma by combining treatments, overcoming resistance, and tailoring therapy to individual patients. The study found promising results using bispecific antibodies in combination with other treatments.
The study found that smokers with myelodysplastic syndromes (MDS) or precursor conditions had elevated levels of genetic mutations linked to the disease. Heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
Dana-Farber Cancer Institute researchers present promising results from two studies on systemic mastocytosis: a novel drug, bezuclastinib, shows early efficacy in treating advanced SM, while a new predictive tool distinguishes between life-threatening and less aggressive forms of the disease with high accuracy
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.